Impact of Novel vs. Usual Brand Menthol Cigarettes on Abuse Liability

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21+
SponsorOhio State University Comprehensive Cancer Center

About this trial

This randomized, double-blind, crossover human laboratory study compares the abuse liability of cigarettes containing menthol and non-menthol cigarette variants, using the participant's usual brand menthol cigarette as a within-subject reference. Participants complete standardized laboratory smoking sessions, behavioral economic tasks, and a naturalistic observational period. The study examines differences in nicotine delivery, smoking behavior, and subjective effects across cigarette types in laboratory and real-world contexts.

Eligibility criteria

Qualifiers

Aged 21 years or older

Currently smoke cigarettes daily (≥ 5 cigarettes/day) for at least the past 6 months, and their usual brand is menthol cigarettes

Willing to provide informed consent

Willing to abstain from all nicotine, tobacco, and smoked cannabis products for approximately 12 hours prior to each study visit

Disqualifiers

Current diagnosis of any significant lung diseases (e.g., asthma, chronic obstructive pulmonary disease, cystic fibrosis)

History of a cardiac event or episode of cardiac distress (e.g., heart attack, hospitalization for chest pain) within the past 3 months

Currently pregnant, planning to become pregnant during the study period, or currently breastfeeding

Self-reported use of any non-cigarette nicotine or tobacco product (e.g., e-cigarettes, cigars, oral nicotine products) or cannabis on more than 10 days in the past 30 days

Trial design

Treatments tested in this trial

  • Biospecimen Collection
  • Questionnaire Administration
  • Cigarette Purchase Task
  • Cross-Price Elasticity Task
  • Daily Diary Surveys
  • Progressive Ratio Task

Treatment groups

48 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Ohio State University Comprehensive Cancer Center

Lead sponsor

National Institute on Drug Abuse (NIDA)

Collaborator